January 26, 2018 / 4:52 PM / 5 months ago

CORRECTED-FDA approves Advanced Accelerator's drug for digestive tract cancer

(Corrects to $3.9 billion from $2.9 billion in paragraph 3)

Jan 26 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved French drugmaker Advanced Accelerator Application SA’s drug to treat patients with a type of digestive tract cancer.

The FDA said the drug, Lutathera, was approved to treat a type of cancer affecting a gastrointestinal tract.

Swiss biotech Novartis AG agreed in October to buy Advanced Accelerator in a $3.9 billion deal. (Reporting by Manas Mishra in Bengaluru; editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below